Health data is changing. Now, big data promises to breathe new life into clinical trial design. So, does this mean […]
Electronic health records (EHRs) are receiving growing attention as a potential source of real-world data. However, their suitability for evaluating […]
Earlier this week the U.S. Food and Drug Administration approved the first new treatment for Alzheimer’s disease in almost 20 […]
A new study has discussed the emerging clinical data for the repurposing of the anti-epileptic drug – Zonisamide – for […]
Since demonstrating efficacy in clinical trials, the monoclonal antibody benralizumab has been licensed for the treatment of severe eosinophilic asthma. […]
A large-scale international trial of a drug for obesity has been hailed as a potential game changer for improving the […]
Current treatments for Parkinson’s disease are mainly dopaminergic drugs. However, these are limited by several side effects and can only […]
For the first time, medication that impacts heart muscle thickness and function, rather than addressing symptoms, is found to treat […]
In a lengthy statement released on Wednesday, FDA staff appeared to endorse Biogen’s treatment for Alzheimer’s disease. If approved, this […]
We recently interviewed Anandbir Brar, Chief Executive Officer of Excelra. Excelra is the lead sponsor for our D4 Global virtual event. […]
